Slowing Disease Progression and Optimizing Quality of Life for Patients With ALS
Webcast
1 AMA PRA Category 1 Credit™ ...Faculty
OVERVIEW
Slowing Disease Progression and Optimizing Quality of Life for Patients With Amyotrophic lateral sclerosis (ALS) is organized by i3 Health.
Dates Available:
July 1, 2025 - June 30, 2026
Statement of Need:
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease characterized by destruction of both upper and lower motor neurons, leading to progressive muscle weakness, paralysis, and death. While no curative options exist, initiating disease-modifying treatment at symptom onset can help to slow the neurodegenerative process of disease progression, significantly ease symptoms, and improve quality of life (Tzeplaeff et al, 2023). Delays in diagnosis hinder early treatment initiation, with an average discrepancy of 9 to 12 months between disease onset and diagnosis. Therefore, it is crucial for members of the ALS care team to remain up to date on strategies for early diagnosis, considerations for selecting disease-modifying therapies, and approaches for enhancing interdisciplinary care. This activity, presented by Richard S. Bedlack, MD, PhD, MS, the Stewart, Hughes and Wendt Distinguished Professor of ALS, Professor of Neurology, and Director of the Duke ALS Clinic at Duke University School of Medicine, will explore strategies for reducing diagnostic delays, slowing disease progression, and optimizing quality of life for patients with ALS.
Learning Objectives:
Upon completion of this activity, participants should be able to:
- Describe signs and symptoms that can enable the early diagnosis of ALS
- Assess considerations that impact selection of disease-modifying therapies (DMTs) for patients with ALS
- Apply strategies to enhance interdisciplinary care for patients with ALS.
ACCREDITATION & CREDITS
Jointly Accredited Provider
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
Physician Assistants/Associates
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 6/30/26. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Nursing Continuing Professional Development
A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.8 ANCC contact hours of pharmacology credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour.
Continuing Pharmacy Education
i3 Health has approved this knowledge-based activity for 1.0 ACPE CE hour. The Universal Activity Number for this activity is JA0008128-0000-25-025-H01-P. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion.
TARGET AUDIENCE
PhysicianNursingPharmacistPhysician AssistantNeurologistsNursesPrimary Care PhysiciansNurse PractitionersOther Health ProfessionalsSPECIALITIES
Neurology
Quick Links